ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency. Cell Cure
NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the UBS Global Healthcare Conference in New York City on Monday, May 18, 2015.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jjzjdp/north_american) has announced the addition of the “North American Ophthalmology Surgery Devices Market by Types, by End-users – Forecast to 2019” report to…
LONDON–(BUSINESS WIRE)–ISG has commenced work on a £4.5 million project to create a state-of-the-art eye hospital in London’s renowned Marylebone medical district, for high-end ophthalmic specialist Optegra. The scheme involves the conversion of two period properties in Queen Anne Street into an advanced facility for the treatment of a comprehensive range of eye conditions. Retaining the attractive Edwardian and Victorian façades of the two buildings, ISG will rationalise and unify space and
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Reports First Quarter 2015 Financial Results
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces two tech evaluation agreements with leading global pharmaceutical company to evaluate use of pSivida’s Durasert technology for ophthalmology.
SAN FRANCISCO–(BUSINESS WIRE)–FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2015. “FibroGen and its partners, AstraZeneca and Astellas, continue to make excellent progress in the global development of roxadustat for the treatment of anemia in patients with chronic kidney disease,” said Thomas B. Neff, chief executive officer of FibroGen. “Patient enrollment in the seven Phase 3 studies re
TOKYO–(BUSINESS WIRE)–HOYA Corporation (TOKYO: 7741) today announced financial results for the fourth quarter and full-year ended March 31, 2015. During the quarter, revenues increased by 10.6% to 127,440 million yen compared with the same period las…
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced financial results for the first quarter ended March 31, 2015 and provided an update on the Company’s business and product development programs.
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced the completion of patient recruitment of its first Phase 3 trial of Fovista® in combination with Lucentis® (ranibizumab).
ACTON, Mass.–(BUSINESS WIRE)–“2015 World Medical Innovation Forum” cites “Early Diagnosis and Treatment of Alzheimer’s Disease” as the top field where breakthroughs will be made
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D., will be a featured speaker at The Common Good Forum “Venture Economics, Public Policy & Investment: Our Nation’s Future” on May 14, 2015, at the Waldorf Astoria in New York City. “Dr. Lanza’s pioneering research is providing hope for millions of people who may one day benefit from breakthrough c
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. “BioTime continues to advance its strategic product development programs. We are currently enrolling patients in a pivotal trial of Renevia™ for the treatment of HIV-associated lipoatrophy,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “At this year’s annual meeting of the American Association for Cancer Resea
DUBLIN–(BUSINESS WIRE)–PRESBIA TO PARTICIPATE IN JEFFERIES HEALTHCARE CONFERENCE
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals Features Key Opinion Leaders in Ophthalmology and Optometry in Analyst and Investor Day Event on May 19
MUNICH–(BUSINESS WIRE)–Our preclinical data support the compound’s potential to protect glaucoma patients’ vision and we see other high medical need diseases that could potentially benefit from TGF-β-targeted treatment.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/d8s63g/seeing_into_the) has announced the addition of the “Seeing into the Future: New Opportunities on the Horizon for Smart Eyewear” report to their offering. T…
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida reports third quarter FY 2015 results; Clear FDA Regulatory Path for Medidur for Posterior Uveitis; NDA filing planned in first half of 2017
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2015. The Company will host a live conference call and webcast at 5:00 p.m. Eastern
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Clinically Relevant, Statistically Significant Improvements of Symptoms in the Late Phase of Allergic Conjunctivitis with EBI-005 Supports Advancing to a Phase 3 Natural Environment Study